Wilms Tumor Protein (WT33 or WT1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Wilms Tumor Protein (WT33 or WT1) – Pipeline Review, H2 2017’, provides in depth analysis on Wilms Tumor Protein (WT33 or WT1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Wilms Tumor Protein (WT33 or WT1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)

The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects

The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

GlaxoSmithKline Plc

Inovio Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Sellas Life Sciences Group Ltd

Sumitomo Dainippon Pharma Co Ltd

Vaximm AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Wilms Tumor Protein (WT33 or WT1) - Overview 7

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Products under Development by Universities/Institutes 17

Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment 20

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development 23

GlaxoSmithKline Plc 23

Inovio Pharmaceuticals Inc 23

Otsuka Holdings Co Ltd 24

Sellas Life Sciences Group Ltd 24

Sumitomo Dainippon Pharma Co Ltd 25

Vaximm AG 26

Wilms Tumor Protein (WT33 or WT1) - Drug Profiles 28

elatipepimut-S + adegrapepimut-S - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

galinpepimut-S - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

GSK-2130579A - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

INO-5401 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

OCV-501 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Vaccine for Oncology - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Vaccine to Target WT1 for Leukemia - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Vaccine to Target WT1 for Oncology - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Vaccine to Target WT1 for Oncology - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Vaccine to Target WT1 for Oncology - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

VXM-06 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

WT-2725 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

WT-4869 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Wilms Tumor Protein (WT33 or WT1) - Dormant Products 50

Wilms Tumor Protein (WT33 or WT1) - Discontinued Products 51

Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones 52

Featured News & Press Releases 52

Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor 52

Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer 52

Sep 14, 2017: SELLAS Galinpepimut-S Induces Specific, Robust and Durable Immune Responses in Patients With High-Risk Multiple Myeloma - Correlated With Clinical Benefit 53

Sep 05, 2017: VAXIMM Presents Preclinical Results For VXM06 Presented at Third CRI-CIMT-EATI-AACR Conference 54

Jul 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome 54

May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017 55

Mar 30, 2017: VAXIMM to present preclinical data on VXM06m at AACR Annual Meeting 2017 55

Mar 01, 2017: SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients 56

Feb 27, 2017: Inovio’s SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy 57

Dec 06, 2016: Boston Biomedical Announces First Clinical Data for Investigational WT1 Cancer Peptide Vaccine, DSP-7888, at ASH Annual Meeting & Exposition 58

Dec 01, 2016: VAXIMM Presents Preclinical Data on VXM-06 at EORTC-NCI-AACR Symposium 59

Nov 04, 2016: Sumitomo Dainippon Pharma Announces the Data of an Investigational WT1 Cancer Peptide Vaccine, DSP-7888 will be Presented at the ASH 2016 60

Oct 19, 2016: SELLAS Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy OfficeR 61

Oct 13, 2016: SELLAS Life Sciences Announces Positive Interim Phase II Results from its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients 62

Oct 03, 2016: SELLAS Life Sciences Appoints Industry Experts to Support Advancement of Cancer Therapeutics Pipeline 63

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16

Number of Products under Investigation by Universities/Institutes, H2 2017 17

Products under Investigation by Universities/Institutes, H2 2017 18

Products under Investigation by Universities/Institutes, H2 2017 (Contd..1), H2 2017 19

Number of Products by Stage and Route of Administration, H2 2017 21

Number of Products by Stage and Molecule Type, H2 2017 22

Pipeline by GlaxoSmithKline Plc, H2 2017 23

Pipeline by Inovio Pharmaceuticals Inc, H2 2017 24

Pipeline by Otsuka Holdings Co Ltd, H2 2017 24

Pipeline by Sellas Life Sciences Group Ltd, H2 2017 25

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 26

Pipeline by Vaximm AG, H2 2017 27

Dormant Projects, H2 2017 50

Discontinued Products, H2 2017 51

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Routes of Administration, H2 2017 20

Number of Products by Stage and Routes of Administration, H2 2017 20

Number of Products by Stage and Molecule Type, H2 2017 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports